Biotech ETF Ripe for Short Sale

02/25/2011 7:00 am EST

Focus: ETFS

Clinical trials aside, one popular biotech ETF has failed a recent technical trial. With key support broken, it now looks likely to continue even lower.

Shares of the Biotech HOLDRS Trust ETF (BBH) have now closed below support three times this week.

The $100.00 level had held as support since December 2010, though BBH did not participate in the strong market rally in early 2011.

The break of support leaves the shares vulnerable to further declines.

Click to Enlarge

There is support at the $96.50 level, the lows reached on November 30, 3010, and then at $95.91, the 50% retracement level for the August 27, 2010-to-January 18, 2011 advance.

The 200-day moving average sits just above $96, and BBH is also now below its 50-day moving average, adding to the bearish short-term case.

By Frank Kollar of

  By clicking submit, you agree to our privacy policy & terms of service.

Related Articles on ETFS

Keyword Image
ETFs & the COT
03/19/2019 9:19 am EST

The moves forecasted by the COT signals make them very adaptable to commodity based ETFs, writes And...